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Abstract
The purpose of this study is to compare the performance of multidetector computed tomography (CT) and positron emission tomography/
CT (PET/CT) with [18F]fluorodeoxyglucose in the diagnosis of multiple solitary lung nodules in 14 consecutive patients with suspicious lung 
cancer. CT and PET/CT findings were reviewed by a radiologist and nuclear medicine physician, respectively, blinded to the  pathological 
diagnoses of lung cancer, considering nodule size, shape, and location (CT) and maximum standardized uptake value normalized to 
body weight (SUVbw max). Nodules were judged malignant or benign. The sensitivity, specificity, and accuracy of the two techniques 
were  compared. CT had a sensitivity, specificity, and accuracy of 93.7, 86.7, and 90.3%, respectively, whereas PET/CT had a sensitivity, 
 specificity, and accuracy of 75, 100, and 87.1%, respectively. Clinical management would have been erroneous in two patients by CT alone 
and in four patients by PET/CT alone. In one patient, the two techniques misdiagnosed the nodules (2 CT and 1 PET/CT). CT and PET/
CT have complimentary roles in characterization of multiple solitary pulmonary nodules. Small nodules are poorly characterized by CT, and 
small-sized low-SUV malignant nodules are difficult to detect with PET/CT.
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Background
Solitary pulmonary nodules (SPNs) are spheroid, well-circumscribed, and radiographic opacities up to 3 cm in diameter completely 
 surrounded by aerated lung, with atelectasis, hilar enlargement, and pleural effusion absent [1, 2]. SPNs are a common incidental finding 
on thoracic X-ray and computed tomography (CT) and are malignant in 10–20% of cases. The presence of risk factors (mainly smoking) 
markedly increases the probability of malignancy, while provenance from certain geographic regions increases the risk that a nodule is 
benign (e.g. tuberculosis related). In addition to size, other nodule features, such as size increase or density change on repeated scan, 
relation to adjacent thoracic structures, and peripheral vs. central position, also influence the probability of malignancy.
In recent years, several studies have assessed the feasibility of screening high-risk populations with low-dose CT to identify SPNs [3–5] 
which may be further investigated by [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) or combined PET/CT. Malignant 
SPNs identified by screening are very often at stage I and have excellent five-year survival after surgery. CT and PET/CT are also used to 
investigate Solitary pulmonary nodules in persons with a previous history of cancer, which are best considered malignant until shown to 
be benign [4].
Computed tomography provides information on nodule size, shape, density, homogeneity, contrast enhancement, and relations with 
adjacent mediastinal and pleural structures. CT may also reveal enlarged mediastinal lymph nodes with a high probability of metastatic 
 involvement [6].
[18F]fluorodeoxyglucose- positron emission tomography reveals increased glucose metabolism, which is a major criterion for distinguishing 
malignant from benign lesions, and has higher accuracy than CT in detecting lymph nodal involvement [7].
Most of the literature has concentrated on solitary lung nodules [8, 9]. However, it is not uncommon to detect several solitary lung  nodules 
in a single patient. The malignant vs. benign nature of all nodules must be ascertained prior to surgery if possible, particularly if located 
in  different lung lobes. This represents a considerable diagnostic challenge. In the present study, we compared the performance of 
 multidetector CT with FDG-PET/CT in the characterization of multiple solitary lung nodules in a consecutive and heterogeneous series of 
patients, some with a previous history of cancer.
Methods
We performed a search in the database of the Thoracic Surgery Division through the association of PET/CT and CT carried out in our 
institution in a series of 2,117 consecutive patients with solid lung nodules. From July 2003 to December 2006, the data of 14 patients with 
two or more nodules >7 mm were obtained and were re-examined by an experienced radiologist and an experienced nuclear medicine 
physician, both blinded to the histological status of the nodules.
Six of the 14 patients had a history of cancer: 1 lung, 3 colon, 1 kidney, and 1 breast; and the nodules were identified during follow-up. In 
the remaining 8 patients, 7 of whom were smokers or former smokers, and the nodules were diagnosed incidentally during investigation 
for other non-oncological conditions. The patients were classified as at high-, intermediate-, or low-risk for cancer. High-risk patients had a 
previous history of cancer; low-risk patients were non-smokers, age below 45 years and with rounded nodules of diameter less than 15 mm; 
all others were considered intermediate risk [10].
Computed tomography
Scans were obtained with a 16-slice GE Light Speed CT (GE Medical Systems, Milwaukee, WI) with the following acquisition parameters: 
collimation 20 mm, reconstructed slice thickness 2.5 mm; standard reconstruction filter; 120 kVp, 220–400 mA (automatic exposure); rota-
tion time 0.8 s; speed 18.75 mm/rot (pitch 0.938). Scans began 50 s after i.v. injection of 1.5 ml/kg of contrast containing 350–370 mg I/ml, 
at 2 ml/s, followed by 50 ml of saline at 2 ml/s.
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The radiologist examined the CT scans, visually assessing lesion size, smooth vs. irregular margins, round vs. oval shape, lesion 
 homogeneity and expressed the result as benign or malignant [11]. The results were classified as true positive (TP), true negative (TN), 
false positive (FP), or false negative (FN) in relation to the histologic findings. Sensitivity (TP/TP+FN), specificity (TN/TN+FP), and accuracy 
(TP+TN/whole population) were then calculated.
Positron emission tomography/computed tomography
In order to improve image quality and to suppress myocardial glucose utilization, patients were asked to refrain from eating carbohydrates 
the day before the examination. On the day of the examination, serum glucose was measured and found to be below 150 mg/dl in all 
cases. Five MBq/kg of [18F]FDG (supplied and quality controlled by an external pharmacy) was administered i.v., under fasting conditions. 
Images were obtained using a PET/CT scanner (Discovery LS; GE Medical Systems, Waukesha, WI). CT settings were 120 kVp, 80 mA, 
5 mm scan width, 3.87–4.25 mm interval in high-sensitivity mode with table speed 15 mm per rotation. Whole body scans were acquired 
from the pelvis to the head in the supine position for a scan time of 24–28 min (4 min per bed position) in 2D mode. Emission data were 
reconstructed using iterative algorithms and corrected for attenuation using transmission data derived from the CT. Attenuation corrected 
images were reconstructed in axial, coronal, and sagittal planes.
The nuclear medicine physician was informed of the presence and position of lung nodules, but was blinded to their pathological status. 
The images were interpreted visually and semi-quantitatively by the measurement of maximum standardized uptake value, normalized to 
body weight (SUVbw max), on axial images, using the corresponding CT image with lung window (reference image) to confirm location. 
Semi-quantitative analysis using SUV was also performed in order to reduce the influence of subjective operator factors.
Because of the mainly vertical respiratory excursion, SUVbw max was also measured for four slices up and four slices down from the 
reference image. Nodules were considered malignant for SUVbw max ≥2.0, benign for SUVbw max <2.0, and classified in relation to the 
pathological findings.
Some patients were included in a clinical protocol approved by our ethical committee. These subjects gave informed consent to the study.
Results
Pathology
The characteristics of the lung nodules found in each patient are shown in Table 1. Mean pathological size was 13.2 mm (SD 12.09 mm; 
range 4–69 mm). Mean pathological size of the benign nodules (n = 15) was 8.07 mm (SD 3.95; range 4–17 mm). Mean pathological size of 
the malignant nodules (n = 16) was 18.73 mm (SD 15.1; range 5–69 mm). Of the benign nodules, 14 were hamartomas and 1 was a focus 
of chronic inflammation. Of the malignant nodules, 10 were primary lung cancer (mean size 22.4 mm; SD 17.6; range 10–69 mm) and 6 
were metastasis (mean size 11.4 mm; SD 6.5; range 5–20 mm). The performances of CT and PET/CT are compared in Table 2.
Re
se
ar
ch
 a
rti
cl
e 
ecancer 2012, 6:266
 4 www.ecancer.org
Table 1: CT and PET/CT findings in relation to histological findings.
First nodule Second nodule Third nodule
Pt Histology CT PET/CT Site Histology CT PET/CT Site Histology CT PET/CT Site
1 NSCLC (spinocellular) TP TP RUL Hamartoma TN TN RLL
2 NSCLC (adenocarcinoma) TP TP LML Hamartoma TN TN RUL
3 NSCLC (spinocellular) TP TP LUL Hamartoma TN TN LUL
4 Metastasis TP TP RLL Hamartoma TN TN LUL
5 NSCLC (spinocellular) TP TP RUL Hamartoma TN TN LUL
6 NSCLC (adenocarcinoma) TP TP RUL Hamartoma TN TN RUL
7 NSCLC (adenocarcinoma) TP TP LUL Hamartoma TN TN LUL
8 NSCLC (adenocarcinoma) TP TP RUL Hamartoma TN TN RLL Chronic 
Inflamm.
FP TN RUL
9 Metastasis TP TP RUL Hamartoma TN TN RLL Metastasis TP FN RUL
10 NSCLC (adenocarcinoma) TP TP LUL Hamartoma TN TN LIL
11 Metastasis FN FN LUL Hamartoma FP TN LIL
12 NSCLC (adenocarcinoma) TP TP RLL Hamartoma TN TN RUL
13 Metastasis TP TP LML Hamartoma TN TN RLL Metastasis TP FN RLL
14 NSCLC (BAC/mucinous) TP FN RLL Hamartoma TN TN RLL
Pt patient, NSCLC non-small cell lung cancer, BAC bronchoalveolar carcinoma, TP true positive, TN true negative, FN false negative,  
FP false positive, RLL right lower lobe, RUL right upper lobe, LIL left lower lobe, LML left middle lobe, LUL left upper lobe
Table 2: Comparison of CT and PET/CT performance.
TP TN FP FN Sensitivity (%) Specificity (%) Accuracy (%)
PET/CT 12 15 0 4 75.0 100.0 87.1
CT 15 13 2 1 93.7 86.7 90.3
TP true positive, TN true negative, FN false negative, FP false positive
Computed tomography
Computed tomography was performed a mean 16 days (range 0–46) before surgery. Thirty-one nodules were identified in the 14 patients: 
21 in the right lung (10 upper lobe, 2 middle lobe, and 9 lower lobe) and 10 in the left lung (8 upper lobe and 2 lower lobe). Margins were 
smooth in 16, irregular in 15. Margins were irregular in 14/17 (82.3%) malignant nodules and smooth in 13/15 (86.7%) benign nodules. 
13/31 (41.9%) nodules were homogeneous: 9/15 (60%) benign nodules were homogeneous and 12/16 (75%) malignant nodules were 
 non-homogeneous. Shape was round in 11 and oval in 19: 6/16 malignant lung nodules were round and 10/16 were oval; 5/15 benign 
nodules were round and 10/15 oval.
Seventeen (54.8%) nodules were judged malignant and 14 (45.2%) benign. Two nodules considered malignant were found to be benign 
(2 FP) (Figure 1) and one nodule considered benign was malignant (1 FN) (Figure 2).
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Figure 1: Lung chronic inflammation. Patient #8. Lung chronic inflammation in the right upper lobe. (a) CT recognized the lung 
nodule as malignant (FP CT) and (b) PET/CT did not reveal increased FDG in relation to the size of the nodule (TP PET/CT).
Figure 2: Lung metastasis. Patient #11. Lung metastasis in the upper left lobe. (a) CT interpreted it as benign (FN CT) as did 
(b) PET (FN PET/CT).
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Positron emission tomography/computed tomography
Positron emission tomography/computed tomography was performed a mean of 15 days (range 0–45) before surgery. Twelve nodules had 
SUVbw max above cut-off (mean 8; range 2.7–16); all were malignant at definitive pathology. The remaining lung nodules (n = 19) had 
SUVbw max <2.
There were four FN findings on PET: two had low-glucose metabolism (Figure 3), one a metastatic lesion from kidney cancer of 5 mm in 
maximum diameter, and the other a primary lung cancer with prominent mucinous component, 20 mm in diameter (Figure 4).
Figure 3: Primary lung cancer. Patient #14. Lung cancer in the right lower lobe as detected by (a) CT (TP CT) and (b) PET/CT did 
not reveal increased FDG uptake (FN PET/CT).
Figure 4: Lung metastasis. Patient #13. Lung metastasis in the right lower lobe. (a) CT detected the malignant nodule (TP CT), 
while (b) PET did not (FN PET/CT).
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Diagnostic accuracy
Nine patients were correctly diagnosed by both techniques, all of whom had only two solitary lung nodules. For one case only (patient 11 
with two nodules), both nodules were wrongly diagnosed: the malignant nodule was considered benign by both techniques, and the benign 
nodule was considered malignant by CT and benign by PET/CT. With regard to the three patients with three solitary nodules, in each case 
one nodule was diagnosed erroneously by one of the two techniques (1 FP by CT; 2 FNs by PET/CT); in each case, the malignancy was 
also present in a lobe containing other nodules and was removed. In one of these patients (patient 8), the third nodule was FP by CT and 
TN by PET/CT, which on resection was found to be a focus of chronic inflammation in a lobe harbouring NSCLC. In patients 9 and 13 with 
three nodules, the third nodule was FN by PET/CT and TP by CT; in each case, the nodule was a metastasis from lung cancer in another 
lobe. In both these cases, the second nodule was correctly identified as benign by both the techniques.
Seven patients had two solitary lung nodules in the same lobe; in three of these (patients 3, 6, and 7), both nodules were correctly 
 diagnosed by both techniques; in the other four cases (patients 8, 9, 13, and 14), one nodule was misdiagnosed, with three FNs by PET/
CT while CT was TP, and one FP by CT while PET/CT was TN.
Seven patients were classified as high risk and seven as intermediate risk. In the high-risk group, sensitivity and specificity were 87.5 and 
83.3%, respectively, for CT, and 62.5 and 100%, respectively, for PET/CT. In the intermediate-risk group, sensitivity and specificity were 
100 and 88.9%, respectively, for CT, and 87.5 and 100%, respectively for PET/CT.
Discussions
Data from the literature mostly concern isolated SPNs and their impact on patient management [8, 9]. In the management of pulmonary 
nodules, surgeons strive to maximize resection rates for early malignant lesions, while avoiding surgery for benign pulmonary nodules, it 
become crucial to recognize the malignant nature of the nodule and to distinguish it from the benign one.
In the present study, we assessed the performance of multidetector CT in comparison to PET/CT in a heterogeneous group of patients 
in the evaluation of two or more SPNs. We found that CT and PET/CT had comparable diagnostic accuracy overall (90.3 vs. 87.1%) in 
the intermediate-risk group (both 94.1%), whereas PET/CT performed worse in the high-risk group (85.7 vs. 78.6%). PET/CT diagnosed 
all benign lesions correctly (specificity 100%), whereas CT misdiagnosed a 6-mm hamartoma and a 12-mm focus of inflammation as 
 malignant (specificity 87.5%).
Positron emission tomography/computed tomography was not as effective as CT at diagnosing malignant nodules in this series, as also 
reported in a previous study [12]. It is worthwhile examining the reasons for the FNs on PET/CT [13, 14]. They were a 5-mm kidney 
 cancer metastasis (patient 11), also considered benign by CT; a 20-mm primary lung adenocarcinoma with mucinous and bronchoalveolar 
 component (patient 14) and two metastases from colorectal cancer of 7.5 mm (patient 9) and 5 mm (patient 13). Thus, two of the four FNs 
were of a histological type known for low rate of glucose metabolism. The 5-mm diameter metastasis was in the right inferior lobe where 
movement can easily lead to underestimation of glucose metabolism. The misdiagnosis of the 7.5-mm lesion can only be interpreted as 
operator error, since SUV was >2. The ‘mitigating’ aspect for patients 9 and 13 is that both had another metastatic lesion, correctly  identified 
by CT and PET/CT. These findings add further weight to the opinion that a semi-quantitative approach does not improve PET/CT  accuracy 
over visual analysis for solid pulmonary lesions characterized by low-FDG uptake, which nonetheless have a low probability of being 
malignant [15].
Although multiple and isolated SPNs have similar causes, for multiple nodules, metastasis is the most likely malignant diagnosis and 
active infectious or inflammatory granulomatous disease the most likely benign cause [16]. The frequency of multiple SPNs varies with 
patient characteristics. In a Japanese study [17], 10% of patients with suspected lung cancer had a second nodule during work-up, and 
60% of these were benign at surgery. Keogan et al [18] reported a second small non-calcified pulmonary nodule on CT in 16% of patients 
with  operable clinical stage I to IIIA NSCLC. The nodules ranged from 4 to 12 mm in diameter: 70% were benign and 11% malignant on 
 pathological examination, with status undetermined in 19%.
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Multiple SPNs are a frequent finding in screening studies. In the Early Lung Cancer Action Project [19], 30% of cancer patients had 
 additional lung nodules characterized as benign on follow-up. In the Mayo Clinic Screening Study [20], over 50% of the 31 volunteers with 
prevalent cancers had other nodules, all but one of which proved to be benign by absence of growth during follow-up.
In patients with extra-pulmonary cancer, an SPN can be a metastasis, primary lung cancer, or benign disease [21]. Metastasis should not 
necessarily preclude surgery, since 5-year survival after metastasectomy can be up to 80% for patients with germ cell tumours, 53% for 
gynaecologic cancers, 44% for head and neck cancer, 43% for renal cell carcinoma, 38% for colon cancer, 34% for sarcoma, 34% for 
breast cancer, and 16% for melanoma [22]. As discussed by Benjamin et al [23], the reported malignancy rate for SPNs in patients with 
extrathoracic malignancy varies widely, from 13 to 87% for small pulmonary nodules. In the study of Ginsberg et al [24] in which small 
nodules (1 cm) detected on CT were removed by video-assisted thoracoscopic surgery, the malignancy rate was 42% in patients with prior 
malignancy. Nevertheless the literature data indicate, as expected, that small nodules in patients with known primary malignancies have a 
higher malignancy rate than those in patients without known primary malignancies.
[18F]fluorodeoxyglucose-positron emission tomography and [18F]fluorodeoxyglucose-positron emission tomography/computed tomography 
PET/CT have been widely used to characterize indeterminate lung nodules identified on CT, with sensitivities ranging from 88 to 96% and 
specificities ranging from 78 to 92% [25]. Yi et al [13] reported that FDG-PET/CT was more sensitive and accurate than dynamic helical 
CT for the detection of malignancy and proposed PET as the first-line method for evaluating SPN. However, in the oncologic  population, 
 Reinhardt et al [14] report a PET sensitivity of 40 and 78% in pulmonary metastases ranging from 5 to 7 mm and from 8 to 10 mm, 
 respectively. The article by Grgic et al [26] found that lesion SUV together with pre-test probability assessment could stratify the risk of 
individual risk of malignancy. The authors also found that higher FDG uptake in lung cancer nodules correlated with poorer survival.
Unfortunately, no data are available regarding the FDG uptake of metastatic lung nodules. However, in this context, FDG-PET can identify 
extra-pulmonary disease, which usually contraindicates thoracic surgery for metastatic lung nodules.
Comparison of the performance of CT and PET/CT relative to pathological findings in a small heterogeneous series of patients with 
multiple SPNs
Conclusions
Our study, although heterogeneous and characterized by a small number of pts, suggests that CT and PET/CT may play complementary 
roles in the characterization of multiple SPNs. It also indicates that their management needs to be carefully evaluated in a multidisciplinary 
setting taking into account clinical data, risk factors, and the results of both diagnostic techniques.
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